Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ASH 2018 | Intestinal microbiota may unlock the true potential of HCT

Jonathan Peled • 17 Jan 2019
ASH 2018
General

Speaking from the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA, Jonathan Peled, MD, PhD, of Memorial Sloan Kettering Cancer Center, New York, NY, discusses the role of the gut microbiota on the clinical outcomes of hematopoietic cell transplantation (HCT) for the treatment of hematological malignancies. This collaborative study found that patients with low intestinal microbiota diversity have poorer clinical outcomes, and Dr Peled discusses the approaches that could be used to boost diversity.

Related Videos

4:33
The EBMT Patient Advocacy Committee: Patient, Family and Donor Day at EBMT 2024
Natacha Bolaños • 16 Apr 2024
2:55
Distinguishing late-onset neutropenia from classical primary neutropenia
Carlo Dufour • 15 Apr 2024
2:39
The MAGIC algorithm probability to predict outcomes of GvHD in the GI tract
James Ferrara • 16 Apr 2024
2:25
The EBMT Trainee Committee: in-person trainee day at EBMT 2024 and upcoming initiatives
Claire Horgan • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals